Unknown

Dataset Information

0

A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs.


ABSTRACT: Inhibition of programmed death 1 (PD-1), expressed on activated T cells, can break through immune resistance and elicit durable responses in human melanoma as well as other types of cancers. Canine oral malignant melanoma is one of the most aggressive tumors bearing poor prognosis due to its high metastatic potency. However, there are few effective treatments for the advanced stages of melanoma in veterinary medicine. Only one previous study indicated the potential of the immune checkpoint inhibitor, anti-canine PD-L1 therapeutic antibody in dogs, and no anti-canine PD-1 therapeutic antibodies are currently available. Here, we developed two therapeutic antibodies, rat-dog chimeric and caninized anti-canine PD-1 monoclonal antibodies and evaluated in vitro functionality for these antibodies. Moreover, we conducted a pilot study to determine their safety profiles and clinical efficacy in spontaneously occurring canine cancers. In conclusion, the anti-canine PD-1 monoclonal antibody was relatively safe and effective in dogs with advanced oral malignant melanoma and other cancers. Thus, our study suggests that PD-1 blockade may be an attractive treatment option in canine cancers.

SUBMITTER: Igase M 

PROVIDER: S-EPMC7591904 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs.

Igase Masaya M   Nemoto Yuki Y   Itamoto Kazuhito K   Tani Kenji K   Nakaichi Munekazu M   Sakurai Masashi M   Sakai Yusuke Y   Noguchi Shunsuke S   Kato Masahiro M   Tsukui Toshihiro T   Mizuno Takuya T  

Scientific reports 20201027 1


Inhibition of programmed death 1 (PD-1), expressed on activated T cells, can break through immune resistance and elicit durable responses in human melanoma as well as other types of cancers. Canine oral malignant melanoma is one of the most aggressive tumors bearing poor prognosis due to its high metastatic potency. However, there are few effective treatments for the advanced stages of melanoma in veterinary medicine. Only one previous study indicated the potential of the immune checkpoint inhib  ...[more]

Similar Datasets

| S-EPMC7881100 | biostudies-literature
| S-EPMC10793675 | biostudies-literature
| S-EPMC8726733 | biostudies-literature
| S-EPMC5027703 | biostudies-literature
| S-EPMC10550157 | biostudies-literature
| S-EPMC6191332 | biostudies-literature
| S-EPMC4898770 | biostudies-literature
| S-EPMC5890037 | biostudies-literature
| S-EPMC7300202 | biostudies-literature
| S-EPMC9200918 | biostudies-literature